Groundbreaking Results from CPC Clinical Research-led STRIDE Trial

This Phase 3b trial suggests that semaglutide 1.0 mg (Ozempic) could become the first therapy in nearly 20 years to gain regulatory approval for improving functional outcomes in patients with peripheral artery disease (PAD) and type 2 diabetes (T2D).
sciences real estate markets in our region, and why Fitzsimons is uniquely positioned to welcome new life sciences companies to our supportive campus.